19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Breast cancer 1 early onset (BRCA1) In vitro and mouse studies suggest small molecules that promote DNA repair could help prevent progression of...
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fatty acid synthase (FASN; FAS) Mouse studies suggest inhibiting FASN could help prevent tumor regrowth after antiangiogenic therapy. In mouse xenograft models of metastatic...
08:00 , Feb 13, 2014 |  BC Innovations  |  Cover Story

Curb your fatty acids

A University of California, San Francisco team has uncovered a pathway for regulating absorption of fatty acids that could yield new targets for treating obesity. MFGE8 , an integrin ligand, controls the uptake of fat...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Hoffmann-La Roche Ltd. regulatory update

Roche's Xenical (orlistat) to treat obesity will be reviewed on May 14 by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee. Xenical, which blocks the absorption of fat from the diet, has been shown to...
08:00 , Nov 12, 2012 |  BioCentury  |  Strategy

Vivus' weighting game

Early sales for Qsymia disappointed investors last week, but Vivus Inc. said the obesity drug's launch reflects the realities of creating a market. The company said it anticipated those realities and expects sales to pick...
07:00 , Aug 6, 2012 |  BioCentury  |  Strategy

Paying to lose

Now that...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Mircera methoxy polyethylene glycol-epoetin beta regulatory update

Roche has rights to Tamiflu, a neuraminidase (NEU1; SIAL1) inhibitor, from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Xeloda is an oral prodrug form of 5-fluorouracil (5-FU). Pegasys is pegylated recombinant interferon (IFN) alfa-2a. Mircera...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
07:00 , May 14, 2012 |  BioCentury  |  Regulation

Lorcaserin's niche

If FDA follows the advice of its advisory committee and approves Arena Pharmaceuticals Inc. 's lorcaserin, the biotech may be able to carve out a niche for the obesity compound despite modest efficacy and potential...